Showing results (61-70 of 184) with videos related to

Sort By:
Pageof 19
Journal of Drug Targeting|April 1, 2016
Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticlesSrinivas Ramishetti, Dalit Landesman-Milo, Dan Peer
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 28, 2016
ECM-based macroporous sponges release essential factors to support the growth of hematopoietic cellsNeta Soffer-Tsur, Dan Peer, Tal Dvir
Expert Opinion on Drug Delivery|September 17, 2014
Overcoming multidrug resistance with nanomedicinesAssaf Ganoth, Keren Cohen Merimi, Dan Peer
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2015
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignanciesShiri Weinstein, Itai A Toker, Rafi Emmanuel, et al.
Drug and Alcohol Dependence|January 14, 2020
The Rapidly Changing US Illicit Drug Market and the Potential for an Improved Early Warning System: Evidence from Ohio Drug Crime LabsDaniel Rosenblum, Jay Unick, Daniel Ciccarone
Nature Nanotechnology|January 31, 2018
A modular platform for targeted RNAi therapeuticsRanit Kedmi, Nuphar Veiga, Srinivas Ramishetti, et al.
Cancer Letters|September 1, 2014
Modulating cancer multidrug resistance by sertraline in combination with a nanomedicineVelthe Drinberg, Rivka Bitcover, Wolf Rajchenbach, et al.
Cancer Research|October 20, 2004
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor modelsDan Peer, Yaron Dekel, Dina Melikhov, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 18, 2022
Delivery strategies of RNA therapeutics to leukocytesDana Tarab-Ravski, Lior Stotsky-Oterin, Dan Peer
Cancer Letters|October 15, 2008
Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimenMirit Argov, Rina Kashi, Dan Peer, et al.
Pageof 19